NATURES SUNSHINE PRODUCTS INC
NATRNasdaqHealthcare · Pharmaceutical Preparations · UT · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $480.1M | $454.4M | $445.3M | $421.9M | $444.1M | $385.2M |
| Operating income | $24.7M | $20.1M | $18.7M | $16.3M | $34.7M | $21.5M |
| Net income | $19.5M | $7.7M | $15.1M | −$390,000 | $30.2M | $23.0M |
| Total assets | $261.1M | $240.9M | $249.8M | $229.8M | $258.9M | $249.5M |
| Total liabilities | $99.6M | $79.9M | $90.2M | $82.7M | $97.5M | $92.3M |
| Equity | $161.6M | $161.0M | $159.5M | $147.0M | $161.4M | $157.2M |
| EPS (diluted) | $1.06 | $0.40 | $0.77 | $-0.02 | $1.42 | $1.07 |
| Shares out. | 18.5M | 18.8M | 19.1M | 19.4M | 19.8M | 19.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 5.2%
- Net margin
- 4.1%
- Return on equity
- 12.1%
- Return on assets
- 7.5%
- Return on capital (ROCE)
- 13.5%
- Liabilities / assets
- 38.1%
- Debt / equity
- 0.62×
- Book value / share
- $8.74
- Revenue growth (YoY)
- 5.7%
- Net income growth (YoY)
- 153.7%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 5.82safe
- Accruals / assets
- −6.1%clean
- Beneish M-Score
- -2.87normal
- Piotroski F-Score
- 6/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 6 good- Operating margin is positive
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Blackrock, Inc.Passive (13G)Oct 17, 2025
- Dimensional Fund Advisors LpPassive (13G)Oct 9, 2025
- Shanghai Fosun Pharmaceutical (Group) Co., Ltd.Activist (13D)Jun 27, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Brower Nathan GOfficer — EVP, General Counsel | May 21, 2026 | Sell | 12,015 | $21.84 |
| Fasching Steven J.Director | May 15, 2026 | Grant | 4,500 | $0.00 |
| Wissmiller HeidiDirector | May 15, 2026 | Grant | 4,500 | $0.00 |
| Yates Bryant JOfficer — EVP & President, Europe | May 15, 2026 | Grant | 8,753 | $0.00 |
| Brower Nathan GOfficer — EVP, General Counsel | May 15, 2026 | Grant | 9,001 | $0.00 |
| May KatieDirector | May 15, 2026 | Grant | 4,500 | $0.00 |
| Fritz Erich AOfficer — EVP, Global Supply Chain | May 15, 2026 | Grant | 9,226 | $0.00 |
| Romanzi Kenneth G.Officer — Chief Executive Officer | May 15, 2026 | Grant | 33,753 | $0.00 |
| Fuller Kevin GregoryOfficer — Global Chief Marketing Officer | May 15, 2026 | Grant | 8,984 | $0.00 |
| Lanoy Jonathan DavidOfficer — SVP, Chief Accounting Officer | May 15, 2026 | Grant | 6,107 | $0.00 |
| Norman Daniel COfficer — EVP & President, Asia | May 15, 2026 | Grant | 11,377 | $0.00 |
| Herbert Kevin R.Officer — EVP & President, North America | May 15, 2026 | Grant | 8,326 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 296,228 | 3.0 | +9.9% |
| Apr 30, 2026 | 269,513 | 4.0 | +20.1% |
| Apr 15, 2026 | 224,356 | 2.6 | -8.7% |
| Mar 31, 2026 | 245,813 | 1.8 | +5.5% |
| Mar 13, 2026 | 233,119 | 1.6 | +12.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer changeMay 11, 2026
- Results of operations · Director / officer change · Shareholder voteMay 7, 2026
- Results of operations · Director / officer changeMar 10, 2026
- Results of operationsNov 6, 2025
- Director / officer change · Regulation FD disclosureOct 15, 2025
- Results of operationsJul 31, 2025
- Entered a material agreementJul 7, 2025
- Entered a material agreementJun 27, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.